From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

naratuximab emtansine   Click here for help

GtoPdb Ligand ID: 9949

Synonyms: IMGN-529 | IMGN529 | K7153A-SMCC-DM1
Immunopharmacology Ligand
Compound class: Antibody
Comment: Naratuximab emtansine (IMGN529) is a CD37- targeting antibody drug conjugate carrying a potent anti-mitotic agent (maytansinoid DM1) payload. This ADC is being investigated for clinical efficacy as a treatment for B cell malignancies, with empahsis on diffuse large B cell lymphoma (DLBCL) in light of preliminary results from the phase 1 clinical trial NCT01534715 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Naratuximab emtansine (IMGN529) has completed Phase 1 clinical trial in patients with B cell malignancies (see NCT01534715) [4]. Naratuximab emtansine was granted EMA orphan designation for the treatment of diffuse large B cell lymphoma (DLBCL) in June 2015 [2], and by the FDA in May 2016 [3].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Naratuximab emtansine induces multiple anti-tumour mechanisms, including apoptosis, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity, and G2/M cell cycle arrest (due to payload delivery) [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01534715 IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Phase 1 Interventional ImmunoGen, Inc.